Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial

Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial

Objectives: To report atypical pathogens from clinical trial data comparing delafloxacin to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia (CABP). Methods: Multiple diagnostic methods were employed to diagnose atypical infections including culture, serology, and...

Full description

Bibliographic Details
Main Authors: Sandra McCurdy, Ashley Nenninger, Amanda Sheets, Kara Keedy, Laura Lawrence, Megan Quintas, Sue Cammarata
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:International Journal of Infectious Diseases
Subjects:
Atypical bacterial pathogens
Community-acquired bacterial pneumonia
Delafloxacin
Fluoroquinolone antibiotics
Clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971220304550

Internet

http://www.sciencedirect.com/science/article/pii/S1201971220304550

Similar Items